ArticleBiochemistry and biophysics reports2025
Alternative splicing immune signature for detecting HBV-related hepatocellular carcinoma in peripheral blood mononuclear cells.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk between alternative splicing and non-coding RNAs in hepatocellular carcinoma: from regulatory mechanism to therapeutic implications.Non-coding RNA research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral blood mononuclear cells (PBMCs) exhibit disease-specific alternative splicing changes that may serve as robust biomarkers for hepatocellular carcinoma (HCC). Nearly half of the 800,000 annual HCC cases arise from chronic HBV, which affects 254 million people globally, underscoring the urgent need for reliable, non-invasive diagnostic tools. We conducted a comprehensive meta-analysis of PBMC transcriptomes, identifying reproducible immune-related alternative splicing events (ASEs) altered in HBV-related HCC. We identified shifts in inferred immune cell composition and ASEs associated with HBV-related HCC and tumor stage. Using eight immune-related ASEs, we trained a random forest classifier on 120 samples from six independent studies to distinguish HBV-related HCC from chronic HBV, non-HBV liver disease, and healthy controls. The model showed excellent performance in cross-validation (N = 120, AUC: 0.97), internal validation on withheld test samples (N = 54, AUC: 0.99), and external validation with two independent cohorts (N = 27, AUC: 1.00). These findings support PBMC splicing signatures as promising non-invasive biomarkers for early detection and surveillance of HBV-related HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.